Receptor News and Research

RSS

Blood pressure drug boosts effectiveness of cancer therapy

In a new Dartmouth Cancer Center (DCC) study led by clinical researcher Tyler J. Curiel, MD, MPH, FACP, investigators found that the FDA-approved blood pressure drug telmisartan can significantly enhance the cancer-killing activity of the targeted therapy olaparib, potentially expanding its use to many more patients.

25 Mar 2026

New pathway enhances brown fat thermogenesis and metabolic health

Researchers have determined how a key protein activates brown fat by expanding blood vessels and nerves in the heat-generating tissue.

25 Mar 2026

New approach helps immune cells find and attack solid tumors

A technique that transforms immune cells into cancer-seeking bloodhounds may overcome a roadblock that has hampered immunotherapy for solid tumors, according to a new study by Stanford Medicine researchers.

24 Mar 2026

CREB5 drives stem cell-like transcriptional programs in aggressive prostate cancer

A new research paper was published in Volume 17 of Oncotarget on March 17, 2026, titled "CREB5 regulates stem cell-like transcriptional programs to enhance tumor progression in prostate cancer."

24 Mar 2026

IGFBP1 identified as potential biomarker for IBD monitoring in elderly patients

A recent study published in Current Molecular Pharmacology highlights the potential of insulin-like growth factor binding protein 1 (IGFBP1) as a monitoring biomarker for disease activity in elderly patients with inflammatory bowel disease (IBD).

24 Mar 2026

Medicare reforms improve medication adherence among older adults with heart disease

Medicare beneficiaries with heart disease or major cardiovascular risk factors reported less cost-related medication non-adherence-skipping or reducing doses, delaying prescription fills or foregoing medications due to cost-after new provisions went into effect limiting out-of-pocket drug costs for Medicare beneficiaries, according to a study being presented at the American College of Cardiology's Annual Scientific Session (ACC.26) and simultaneously published in JACC, the flagship journal of the ACC.

24 Mar 2026

Gut microbes drive fat browning in response to diet

White adipose tissue stores energy, while brown and beige fat burn energy through thermogenesis. Under certain environmental conditions, white fat can transition into beige fat in a process known as browning.

24 Mar 2026

Study revises the understanding of neutrophil dynamics during respiratory viral infection

Neutrophil infiltration is a hallmark of pulmonary inflammation during respiratory viral infections, yet the origin of these cells has been a subject of debate.

23 Mar 2026

Oral semaglutide fails to slow early Alzheimer’s decline in two phase 3 trials

Two large phase 3 trials found that oral semaglutide 14 mg did not slow cognitive or functional decline over 104 weeks in people with early symptomatic, amyloid-positive Alzheimer’s disease. Semaglutide was generally consistent with its known safety profile and showed some biomarker changes, but these did not translate into clinical benefit.

22 Mar 2026

GLP-1 drugs cut heart and kidney risks in type 1 diabetes study

In a large target trial emulation of 174,678 people with type 1 diabetes, GLP-1 receptor agonist initiation was associated with lower risks of major cardiovascular events and end-stage kidney disease over five years. The study also found no increased risk of hospitalization for diabetic ketoacidosis or severe hypoglycemia, supporting further randomized trials of GLP-1RAs as adjunctive therapy in type 1 diabetes.

22 Mar 2026

Do artificial sweeteners increase appetite or food intake?

The study evaluates artificial sweeteners' role in appetite regulation, showing no significant effects on hunger or energy intake during weight management.

20 Mar 2026

Scientists reveal how light-activated drugs change receptor activity

Rendering a drug effective or ineffective in a flash at the appropriate location – this is the focus of research in photopharmacology.

19 Mar 2026

Blood-based test helps personalize breast cancer care for older patients

For women age 70 and over with a common form of breast cancer, determining "the right size" of treatment can be challenging, in part because clinicians have limited tools to guide individualized treatment decisions.

19 Mar 2026

How long should you take GLP-1 drugs? Study links longer use to lower heart risk

Continuous use of GLP-1 receptor agonists in adults with type 2 diabetes was associated with a lower risk of major cardiovascular events compared with sulfonylureas, with benefits increasing over time. Discontinuation or interruption was associated with a progressive loss of this protective effect, with risks approaching those of comparator therapy.

19 Mar 2026

GLP-1 medications linked to reduced psychiatric hospital visits

GLP-1 medications used to treat diabetes and obesity were associated with a reduced need for hospital care and sickness absence due to psychiatric reasons, a new study shows.

18 Mar 2026

New mechanism drives adverse tumor remodeling during breast cancer progression

A research group led by Professor Cecilia Sahlgren at Åbo Akademi University (Finland) and the InFLAMES Research Flagship has identified a new mechanism directing the adverse remodeling of tumor tissue during breast cancer progression.

18 Mar 2026

Precise application of radio waves could help counter neurological conditions

A new study found that precise application of radio waves can change the activity of brain cells in ways that could counter neurological conditions.

18 Mar 2026

Study finds GLP-1 medicines cut fat while preserving muscle function

Researchers found that GLP-1 medicines caused weight loss mainly through fat reduction, with only modest decreases in absolute muscle mass and no disproportionate loss of muscle function. In mice, physical performance improved, while in a small 12-week human pilot trial, strength was preserved despite reduced thigh muscle size.

18 Mar 2026

Muscle-repairing macrophages trigger heterotopic ossification in mice

We have identified a macrophage population "Mrep" that plays an essential role in muscle repair. However, in Fibrodysplasia ossificans progressiva (FOP), Mrep functions as a pathogenic cell that triggers heterotopic ossification.

18 Mar 2026

Key gene mutation disrupts the brain’s ability to update beliefs in schizophrenia patients

One of the symptoms of schizophrenia is difficulty incorporating new information about the world. This can lead patients to struggle with making decisions and, eventually, to lose touch with reality.

18 Mar 2026